POINT Biopharma Global Inc.

POINT Biopharma Global Inc. (Nasdaq: PNT) is a radiopharmaceutical company focused on developing and commercializing targeted radioligand therapies for oncology indications. The company entered the public markets in 2021 through a business combination with GX Acquisition Corp. II, sponsored by GX Capital Management LLC, and listed on Nasdaq under the ticker PNT. By October 2023, when the company submitted the referenced 8-K filing with the SEC, POINT Biopharma had entered into a definitive agreement to be acquired by Eli Lilly and Company in an all-cash transaction, representing a notable de-SPAC exit in the precision oncology sector. Sign up at SpacDesk for full filing histories, sponsor profiles, and deal timelines on POINT Biopharma and hundreds of other SPAC transactions.